This segment focuses on the research and development of therapeutics for rare, debilitating, and potentially life-threatening diseases. The primary focus is on QLS-215, a monoclonal antibody inhibitor of plasma kallikrein, currently in preclinical development for the treatment of hereditary angioedema (HAE). Research and development activities include preclinical studies, clinical trial design, and regulatory submissions. The company utilizes advanced biotechnology and antibody engineering to develop targeted therapies. The goal is to improve the quality of life for patients suffering from HAE by reducing the frequency and severity of attacks. Market positioning involves targeting a niche market with high unmet medical needs. Future opportunities include expanding the pipeline to address other rare diseases and exploring strategic partnerships to accelerate development and commercialization. Regulatory aspects involve navigating the FDA approval process for orphan drugs. Collaborations with patient advocacy groups and research institutions are crucial for clinical trial recruitment and disease awareness.